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To reduce over-diagnosis of chronic kidney disease (CKD) resulting from the inaccuracy of
creatinine-based estimates of glomerular filtration rate (GFR), UK and international guide-
lines recommend that cystatin-C-based estimates of GFR be used to confirm or exclude the
diagnosis in people with GFR 45–59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1).
Whilst there is good evidence for cystatin C being a marker of GFR and risk in people with
CKD, its use to define CKD in this manner has not been evaluated in primary care, the set-
ting in which most people with GFR in this range are managed.
Methods and findings
A total of 1,741 people with CKD G3a or G3b defined by 2 estimated GFR (eGFR) values
more than 90 days apart were recruited to the Renal Risk in Derby study between June
2008 and March 2010. Using Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equations, we compared GFR estimated from creatinine (eGFRcreat), cystatin C
(eGFRcys), and both (eGFRcreat-cys) at baseline and over 5 years of follow-up. We analysed
the proportion of participants with CKD G3aA1 reclassified to ‘no CKD’ or more advanced
CKD with the latter two equations. We further assessed the impact of using cystatin-C-
based eGFR in risk prediction equations for CKD progression and all-cause mortality and
investigated non-GFR determinants of eGFRcys. Finally, we estimated the cost implications
of implementing National Institute for Health and Care Excellence (NICE) guidance to use
eGFRcys to confirm the diagnosis in people classified as CKD G3aA1 by eGFRcreat. Mean
eGFRcys was significantly lower than mean eGFRcreat (45.1 ml/min/1.73 m
2, 95% CI 44.4 to
45.9, versus 53.6 ml/min/1.73 m2, 95% CI 53.0 to 54.1, P < 0.001). eGFRcys reclassified
7.7% (50 of 653) of those with CKD G3aA1 by eGFRcreat to eGFR 60 ml/min/1.73 m
2.
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However, a much greater proportion (59.0%, 385 of 653) were classified to an eGFR cate-
gory indicating more severe CKD. A similar pattern was seen using eGFRcreat-cys, but lower
proportions were reclassified. Change in eGFRcreat and eGFRcys over 5 years were weakly
correlated (r = 0.33, P < 0.001), but eGFRcys identified more people as having CKD progres-
sion (18.2% versus 10.5%). Multivariable analysis using eGFRcreat as an independent vari-
able identified age, smoking status, body mass index, haemoglobin, serum uric acid, serum
albumin, albuminuria, and C reactive protein as non-GFR determinants of eGFRcys. Use of
eGFRcys or eGFRcreat-cys did not improve discrimination in risk prediction models for CKD
progression and all-cause mortality compared to similar models with eGFRcreat. Application
of the NICE guidance, which assumed cost savings, to participants with CKD G3aA1 in-
creased the cost of monitoring by £23 per patient, which if extrapolated to be applied
throughout England would increase the cost of testing and monitoring CKD by approxi-
mately £31 million per year. Limitations of this study include the lack of a measured GFR
and the potential lack of ethnic diversity in the study cohort.
Conclusions
Implementation of current guidelines on eGFRcys testing in our study population of older
people in primary care resulted in only a small reduction in diagnosed CKD but classified a
greater proportion as having more advanced CKD than eGFRcreat. Use of eGFRcys did not
improve risk prediction in this population and was associated with increased cost. Our data
therefore do not support implementation of these recommendations in primary care. Further
studies are warranted to define the most appropriate clinical application of eGFRcys and
eGFRcreat-cys.
Author summary
Why was this study done?
• Estimation of kidney function (glomerular filtration rate) from serum creatinine con-
centration may be inaccurate in some people due to the impact of muscle mass, diet,
and drugs on creatinine concentration.
• To reduce over-diagnosis of chronic kidney disease, international and UK guidelines rec-
ommend that the diagnosis of chronic kidney disease should be confirmed with an estimate
of kidney function based on a different marker of glomerular filtration, cystatin C, in those
people with only a mild reduction in glomerular filtration rate and no albuminuria.
• The clinical utility of this guidance has not been adequately evaluated in primary care,
the setting in which most people with chronic kidney disease are cared for.
What did the researchers do and find?
• We estimated glomerular filtration rate from serum creatinine and cystatin C in a
cohort of 1,741 mainly older people diagnosed with chronic kidney disease in primary
care.
Cystatin C in primary care
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• The use of cystatin C to confirm a diagnosis of chronic kidney disease resulted in reclas-
sification of a small proportion (7.7%) of people as not having chronic kidney disease,
but a much greater proportion were reclassified as having more advanced disease (59%).
• In this cohort, the use of cystatin C did not result in improved risk prediction for all-
cause mortality or progression of chronic kidney disease.
• We estimate that the use of cystatin C as recommended in current guidelines would
result in increased healthcare costs of £23 per person in the first year of implementation.
What do these findings mean?
• Our data do not support the use of cystatin C to confirm a diagnosis of chronic kidney
disease in primary care.
• Cystatin C may be useful for estimating glomerular filtration rate in other settings
where creatinine is known to be unreliable, for example in people with extremes of body
habitus.
Introduction
The use of serum creatinine concentration to estimate glomerular filtration rate (GFR) has
become widely adopted as the principal test for the diagnosis of chronic kidney disease (CKD).
However, the dependence of serum creatinine on muscle mass and the tendency of creatinine-
based equations to underestimate GFR at values close to the diagnostic threshold of 60 ml/
min/1.73 m2 has raised concerns about the risk of over-diagnosis in otherwise healthy older
populations when relying on this method and has prompted calls to identify more reliable
endogenous filtration markers for the estimation of GFR [1]. Concern has also been expressed
that the use of GFR estimated from creatinine but not corrected for age may result in under-
diagnosis of CKD in younger people [2]. Cystatin C, a protein that normally crosses the glo-
merular filtration barrier, has been proposed as an alternative endogenous marker. Cystatin C
is produced by all nucleated cells, and is therefore less influenced by muscle mass than creati-
nine [1,3,4]. Though estimation of GFR from cystatin C alone was found to be no more accu-
rate than creatinine, estimated GFR (eGFR) derived from a combined creatinine and cystatin
C equation was more accurate and showed greater precision than eGFR derived from creati-
nine or cystatin C alone [5].
National Institute for Health and Care Excellence (NICE) and Kidney Disease Improving
Global Outcomes (KDIGO) guidance for the diagnosis of CKD stage 3 have recommended use
of cystatin-C-based eGFR to confirm or exclude a diagnosis in those found to have a creati-
nine-based eGFR between 45 and 59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1) [6,7].
However, the clinical impact and cost of implementing this recommendation has not been
adequately evaluated in the population in which it will be applied: those with mildly reduced
eGFR, managed predominantly in primary care. This is important because this group repre-
sents the majority of people defined as having CKD. Population-based studies have reported
that 3.6% of adults in the US [8] and 3.2% of adults in the UK are in CKD stage G3aA1 [9].
Additionally, whilst cystatin C is not dependent on muscle mass, it has been reported to have
Cystatin C in primary care
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other non-GFR determinants including sex, inflammation, obesity, diabetes, smoking, and
thyroid dysfunction that may adversely affect GFR estimation in some populations [10–14].
Cystatin C has also been shown to improve discrimination in equations to predict adverse
outcomes in CKD stage 3 including end-stage kidney disease (ESKD) [15], all-cause mortality
[15], and cardiovascular mortality [16]. Potentially, therefore, its use in the diagnosis and con-
tinuing evaluation of people with CKD in primary care may improve our ability to detect indi-
viduals at high risk of adverse outcomes, to facilitate targeted monitoring and intervention
including early referral to a nephrology service [17]. However, as yet there is little published
evidence regarding the use of cystatin-C-based estimates of GFR for risk assessment in pri-
mary care.
In this analysis, we aimed to assess the impact of use of cystatin-C-based and combined cre-
atinine and cystatin C eGFR compared to standard creatinine-based estimates in a primary
care population with baseline CKD stage 3, defined by 2 measures of GFR more than 90 days
apart, and to evaluate the non-GFR determinants of cystatin-C-based eGFR. Additionally, we
compared creatinine- and cystatin-C-based estimates of GFR over 5 years of follow-up and
evaluated the prognostic accuracy of cystatin C in risk prediction. Finally, we evaluated the
cost implications of implementing NICE guidance to confirm a diagnosis of CKD G3aA1
based on creatinine eGFR (eGFRcreat) by checking cystatin C eGFR (eGFRcys) and also consid-
ered the use of creatinine and cystatin C eGFR (eGFRcreat-cys) as an alternative strategy.
Methods
Ethics
The Renal Risk in Derby (RRID) study was approved by the Nottingham Research Ethics
Committee 1, and is included in the National Institute for Health Research Clinical Research
Network Portfolio (NIHR Study ID. 6632). All participants provided written informed consent
at study baseline, and repeated the consent at the year 5 study visit. The RRID study complies
with the Declaration of Helsinki and the principles of good clinical practice.
Participants
Detailed methods for the RRID study have been published previously [18]. The study protocol
and STROBE and STARD checklists are also available (S1 Protocol; S1 STROBE Checklist; S1
STARD Checklist). In all, 1,741 participants were individually recruited and prospectively
studied from 32 Derbyshire primary care practices between June 2008 and March 2010. To
start, 8,280 people were invited from practice registers of patients with CKD stage 3. Of these,
1,822 people attended baseline visits. All participants were aged over 18 years. Participants
were selected using the 4-variable Modification of Diet in Renal Disease (MDRD) equation
modified for use with isotope dilution mass spectrometry–standardised creatinine measure-
ment. Two MDRD eGFR results consistent with CKD stage 3 (30–59 ml/min/1.73 m2) more
than 90 days apart were required to be eligible. People who were judged to have a life expec-
tancy of less than 1 year, were unable to attend study visits at their primary care surgery, or
had previously received a solid organ transplant were excluded from the study. Of the 1,822
people who attended baseline visits, 1,741 were eligible and therefore included in the study
cohort (Fig 1).
Study visits
Study visits were conducted at baseline and repeated at 1 and 5 years. Prior to each visit, partic-
ipants completed a background questionnaire covering demographic details, medical history,
Cystatin C in primary care
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smoking history, and medication history. Participants’ responses to questions were reviewed
at the study visit and clarified as required. At each clinical visit, the participant’s height, weight,
and waist and hip circumference were measured. Three blood pressure measurements were
taken using an oscillometric device (UA-767 Plus 30, A&D Medical) after at least 5 minutes of
rest. Readings were repeated until values differed by no more than 10%.
Laboratory methods
Participants collected 3 consecutive days’ early morning urine samples and stored these in a
refrigerator prior to their study visit for subsequent albumin and creatinine analysis. The
mean urine albumin-to-creatinine ratio (uACR) from the 3 specimens was used for analysis.
Blood samples were taken at each study visit. Participants were asked to abstain from eating
meat for 12 hours prior to the study visit to avoid confounding the serum creatinine assay
[19]. Blood and urine samples were analysed in a single clinical laboratory at the Royal Derby
Hospital for standard haematological and biochemical variables. Creatinine was measured
using a compensated Jaffe method, standardised against an isotope dilution mass spectrometry
method, with an inter-assay coefficient of variance of 2.3% at 96 mmol/l (Roche P-analyser,
Roche Diagnostics). Cystatin C was measured from serum samples taken at baseline, year 1,
and year 5 study visits, stored at −80˚C. Measurement was undertaken at the biochemistry lab-
oratory at the John Radcliffe Hospital, Oxford, UK, using a particle-enhanced turbidimetric
immunoassay assay (Abbott c16000 Analyser, Abbott Diagnostics) calibrated against the inter-
national reference material ERM-DA471/IFCC.63. The assay used has a coefficient of variation
of 1.5% at 0.89 mg/l and 1.1% at 4.06 mg/l.
Estimating equations
This analysis compared GFR estimated using the creatinine-based, cystatin-C-based, and com-
bined equations developed by the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI), designated eGFRcreat, eGFRcys, and eGFRcreat-cys, respectively [5,20].
Outcome definitions
We used KDIGO definitions to classify participants’ CKD stage according to eGFRcreat,
eGFRcys, and eGFRcreat-cys. The study prespecified endpoint for CKD progression was the
development of ESKD or doubling of serum creatinine. However, this endpoint was observed
in only 4 participants (0.2%) after 5 years [21], and we therefore used the KDIGO definition of
CKD progression, which is a 25% or more loss of GFR coupled with a worsening of eGFR cate-
gory or a worsening of albuminuria category [6]. Date and cause of death as stated on death
certificates was obtained from the Office for National Statistics via the Health and Social Care
Information Centre.
Statistical analysis
Analysis was conducted according to a prospective analysis plan (see S1 Protocol and S1 Text).
Baseline variables were compared according to quartiles of cystatin C, using ANOVA, Krus-
kal–Wallis, or chi-squared tests as appropriate. Participants were classified according to
KDIGO eGFR category initially using eGFRcreat. Reclassification was undertaken using both
eGFRcys and eGFRcreat-cys. Bland–Altman plots were produced to measure the difference
Fig 1. Flow chart for participants invited and recruited into the study, and numbers involved at key time points. CKD, chronic kidney
disease; KDIGO, Kidney Disease Improving Global Outcomes.
https://doi.org/10.1371/journal.pmed.1002400.g001
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between eGFRcreat and both eGFRcys and eGFRcreat-cys across the range of eGFR values. Multi-
variable linear regression models were constructed using eGFRcys as the dependent variable
and eGFRcreat as well as clinical variables previously reported as non-GFR determinants of
cystatin C as covariates. Non-normally distributed variables (uACR, high-sensitivity C-reactive
protein [hsCRP]) were logarithmically transformed prior to multivariable analysis.
We have previously reported multivariable models predicting risk of CKD progression
(using the KDIGO definition) and all-cause mortality developed in this cohort [21]. Compari-
son of these models was undertaken using eGFRcys and eGFRcreat-cys in place of eGFRcreat.
Binomial logistic regression models were compared using area under the receiver operating
characteristic curve (AUROC) based upon predicted probability of progression.
Cost impact analysis
We used the findings of this study to estimate the cost consequences of implementing cystatin
C testing and subsequent monitoring for 12 months as recommended in NICE CKD guide-
lines for patients with CKD G3aA1 [7]. We assumed that the re-categorising of patients led to
the following changes in monitoring by reclassified group: (i) for those classified CKD G3a (no
CKD, with diabetes), monitoring continued unchanged, with general practitioner (GP) annual
follow-up (eGFR and uACR testing), as recommended by NICE; (ii) for those reclassified as
no CKD and without diabetes, the eGFR and uACR tests were dropped from routine monitor-
ing; (iii) for those reclassified as G3b, additional monitoring was added, with eGFR and uACR
testing every 6 months via an additional practice nurse consultation; (iv) for those reclassified
as G4 or G5, each had a new nephrology outpatient consultation with detailed blood testing
and ultrasound, followed by biannual eGFR and uACR testing. The relevant unit costs are
shown in Table 1, using costs published by NICE updated to 2015 prices [7].
Results
Baseline data
Cystatin C was measured from stored samples in 1,732 participants at baseline. Baseline values
for key variables for this cohort are given in Table 2. Mean ± standard deviation values for
eGFRcreat, eGFRcys, and eGFRcreat-cys were 53.6 ± 11.8, 45.1 ± 16.0, and 48.3 ± 12.9 ml/min/
1.73 m2, respectively (P< 0.001 for eGFRcys and eGFRcreat-cys versus eGFRcreat). Higher cysta-
tin C was associated with male sex, higher prevalence of previous cardiovascular disease and
diabetes mellitus, greater body mass index (BMI), greater waist-to-hip ratio, higher systolic
blood pressure, and lower diastolic blood pressure. Haemoglobin, total cholesterol, and serum
bicarbonate concentration were lower, and serum uric acid and uACR were higher, in quar-
tiles with higher cystatin C (Table 2).
Table 1. Unit costs.
Unit costs derived from NICE1, updated to 2015 Amount in British pounds
GP annual (simple) consultation for eGFR and uACR 37.50
Practice nurse consultation with phlebotomy 13.23
eGFR and uACR test 6.19
Nephrology first outpatient consultation including ultrasound scan 292.77
1Chronic kidney disease guideline appendices A–R [22].
eGFR, estimated glomerular filtration rate; GP, general practitioner; NICE, National Institute for Health and
Care Excellence; uACR, urine albumin-to-creatinine ratio.
https://doi.org/10.1371/journal.pmed.1002400.t001
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A comparison of the frequency of people in each eGFR category using the different equations
is shown in Fig 2. Fewer participants had a baseline eGFR 60 ml/min/1.73 m2 using either
eGFRcys or eGFRcreat-cys compared to eGFRcreat. Similarly, both eGFRcys and eGFRcreat-cys classi-
fied more participants as having CKD G3b/G4 disease compared to eGFRcreat.
The use of eGFRcys in the 653 people with eGFRcreat CKD G3aA1 at baseline reclassified 50
(7.7%) to eGFR 60 ml/min/1.73 m2 (i.e., no CKD), 356 (54.5%) to G3b, and 29 (4.5%) to G4
or G5. Similarly, using eGFRcreat-cys reclassified 36 (5.5%) to no CKD, 239 (36.6%) to G3b, and
2 (0.3%) to G4 or G5 (Table 3). Application of eGFRcys to the whole study population reclassi-
fied 57 of 784 (7.3%) with eGFRcreat CKD G3a to eGFR 60 ml/min/1.73 m
2 and 488 (62.2%)
to CKD G3b or worse (Table 4). Similarly, in the whole study population, eGFRcreat-cys reclassi-
fied 4.7% of participants (37 of 784) with eGFRcreat CKD G3a to eGFR> 60 ml/min/1.73 m
2
and 311 (39.7%) to CKD G3b or G4 (Table 5).
Bland–Altman plots
Bland–Altman plots in the whole cohort showed that for the majority of participants, eGFRcreat
was greater than eGFRcys and eGFRcreat-cys (Fig 3). Mean difference was +8.4 ml/min/1.73 m
2
Table 2. Baseline variables by quartile of baseline cystatin C.
Variable All participants (n =
1,732)
Participants by cystatin C quartile P value for
trendQuartile 1 (n =
444)
Quartile 2 (n =
432)
Quartile 3 (n =
431)
Quartile 4 (n =
425)
eGFRcreat (ml/min/1.73 m
2) 53.6 ± 11.8 63.6 ± 9.7 57.4 ± 7.4 51.1 ± 8.1 41.7 ± 8.9 <0.001
eGFRcys (ml/min/1.73 m
2) 45.1 ± 16.0 65.5 ± 14.4 47.7 ± 3.8 38.6 ± 3.0 27.9 ± 4.9 <0.001
eGFRcreat-cys (ml/min/1.73
m2)
48.3 ± 12.9 64.0 ± 9.2 51.7 ± 4.3 43.7 ± 4.3 33.2 ± 5.7 <0.001
Age (years) 72.9 + 9.0 68.6 ± 9.0 72.2 ± 8.3 74.4 ± 8.1 76.4 ± 8.8 0.19
Female sex 1,047 (60.4%) 350 (78.8%) 270 (62.5%) 230 (53.4%) 197 (46.4%) <0.001
Diabetes 292 (16.9%) 43 (9.7%) 60 (13.9%) 92 (21.3%) 97 (22.8%) <0.001
Current smoker 81 (4.7%) 17 (3.8%) 18 (4.2%) 18 (4.2%) 28 (6.6%) 0.20
Previous CVD 385 (22.2%) 67 (15.1%) 84 (19.4%) 111 (25.8%) 123 (28.9%) <0.001
Thyroid disorder 217 (12.5%) 61 (13.7%) 58 (13.4%) 44 (10.2%) 54 (12.7%) 0.39
Haemoglobin (g/l) 132 ± 14 135 ± 13 134 ± 13 133 ± 14 128 ± 16 <0.001
Corrected calcium (mmol/l) 2.38 ± 0.10 2.38 ± 0.10 2.38 ± 0.09 2.38 ± 0.10 2.37 ± 0.10 0.37
Phosphate (mmol/l) 1.11 ± 0.18 1.11 ± 0.18 1.10 ± 0.19 1.09 ± 0.16 1.12 ± 0.18 0.07
Albumin (g/l) 40.7 ± 3.2 41.3 ± 3.0 41.0 ± 3.0 40.4 ± 3.1 40.0 ± 3.5 0.28
Bicarbonate (mmol/l) 25.5 ± 2.7 26.1 ± 2.4 25.7 ± 2.5 25.4 ± 2.7 24.9 ± 3.0 <0.001
Total cholesterol (mmol/l) 4.8 ± 1.2 5.1 ± 1.1 4.8 ± 1.1 4.7 ± 1.2 4.5 ± 1.2 0.04
Uric acid (μmol/l) 384 ± 91 334 ± 75 364 ± 76 398 ± 78 443 ± 96 <0.001
BMI (kg/m2) 29.0 ± 5.1 28.4 ± 4.9 28.7 ± 4.7 29.3 ± 4.8 29.7 ± 5.9 0.003
Waist-to-hip ratio 0.91 ± 0.09 0.87 ± 0.08 0.90 ± 0.09 0.92 ± 0.08 0.94 ± 0.09 0.001
SBP (mm Hg) 134 ± 18 133 ± 18 134 ± 17 135 ± 18 134 ± 21 0.001
DBP (mm Hg) 73 ± 11 76 ± 11 73 ± 10 73 ± 11 70 ± 11 0.008
uACR (mg/mmol) 0.33 (0.00–1.50) 0.13 (0.00–0.58) 0.16 (0.00–0.97) 0.50 (0.00–2.07) 1.17 (0.15–4.20) <0.001
hsCRP (mg/l) 2.2 (1.1–4.6) 1.7 (0.8–3.4) 2.0 (1.1–3.6) 2.5 (1.3–5.5) 3.3 (1.7–6.2) <0.001
Data shown are mean ± standard deviation, number (percent), or median (lower quartile–upper quartile).
BMI, body mass index; creat, creatinine; cys, cystatin C; creat-cys, creatinine and cystatin C; CVD, cardiovascular disease; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; SBP, systolic blood pressure; uACR, urine albumin-to-creatinine
ratio.
https://doi.org/10.1371/journal.pmed.1002400.t002
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between eGFRcreat and eGFRcys and +5.3 ml/min/1.73 m
2 between eGFRcreat and eGFRcreat-cys.
Both plots showed a small minority of cases, at higher mean eGFR, for which eGFRcys or
eGFRcreat-cys was greater than eGFRcreat.
Non-GFR determinants of eGFRcys
Non-GFR determinants of eGFRcys at baseline were assessed using linear regression, with cor-
rection for baseline eGFRcreat. In fully adjusted models, a range of factors remained significant
including age, smoking status, and BMI. Other significant determinants included markers of
inflammation and non-traditional cardiovascular risk factors (haemoglobin, uric acid, albu-
min, uACR, and hsCRP) (S1 Table).
Fig 2. Histogram showing frequency of people in each eGFR category at baseline using different estimating equations. creat,
creatinine; cys, cystatin C; creat-cys, creatinine and cystatin C; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration
rate.
https://doi.org/10.1371/journal.pmed.1002400.g002
Table 3. Reclassification in 653 participants classified as CKD G3aA1 by eGFRcreat at baseline using eGFRcys and eGFRcreat-cys.
Estimating equation eGFR 60 ml/min/1.73 m2 CKD G3a CKD G3b CKD 4 CKD 5
eGFRcys 50 (7.7%) 218 (33.4%) 356 (54.5%) 28 (4.3%) 1 (0.2%)
eGFRcreat-cys 36 (5.5%) 376 (57.6%) 239 (36.6%) 2 (6.3%) 0
Data shown are number (percent).
CKD, chronic kidney disease; creat, creatinine; cys, cystatin C; creat-cys, creatinine and cystatin C; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pmed.1002400.t003
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Change in eGFR over 5 years
Nine hundred ninety-nine participants had cystatin C measured at both baseline and year 5
(Fig 1). There was a weak correlation between 5-year change in eGFRcys and 5-year change in
eGFRcreat (Pearson’s correlation coefficient, r = 0.33, P< 0.001), and a moderate correlation
between 5-year change in eGFRcreat-cys and 5-year change in eGFRcreat (r = 0.76, P< 0.001).
Over 5 years, the KDIGO definition for CKD progression based on 25% loss of eGFR and a
worsening of eGFR category or albuminuria category was met in 105 of 999 participants
(10.5%) using eGFRcreat, 182 (18.2%) using eGFRcys, and 135 (13.5%) using eGFRcreat-cys.
Risk prediction
Overall, 306 participants (17.7%) met the KDIGO criteria for CKD progression at 5 years, and
247 (14.2%) died. Replacing baseline eGFRcreat with eGFRcys or eGFRcreat-cys in previously
developed multivariable prediction models for CKD progression [21] did not improve dis-
crimination. The AUROC was comparable for all 3 models (Table 6). Similarly, in multivari-
able Cox proportional hazards models for all-cause mortality over 5 years, similar hazard
ratios were obtained for eGFR with each estimating equation (Table 6).
Cost impact
The impacts on National Health Service (NHS) costs for groups reclassified with CKD G3aA1
by eGFRcys or eGFRcreat-cys are summarised in Table 7, based on conservative assumptions.
The direct cost of adding eGFRcys testing to existing tests would be fairly low based on NICE’s
estimated cost of just over £3 per test. However, the total cost impact of providing recom-
mended monitoring and referral would be much greater, at £20 per person (£12,843 for the
653 persons in this study). Thus, the combined total cost impact would be an increase of £23
(£20 + £3) per person. This impact would be less if using the combined eGFRcreat-cys equation,
Table 4. Baseline eGFRcreat category and reclassification using eGFRcys in all study participants.
Baseline eGFRcreat category eGFRcys category Total
G1/G2 G3a G3b G4 G5
G1/G2 182 (34.1%) 251 (47.1%) 96 (18.0%) 4 (0.8%) 0 533 (30.8%)
G3a 57 (7.3%) 239 (30.5%) 446 (56.9%) 41 (5.2%) 1 (0.1%) 784 (45.2%)
G3b 10 (2.6%) 12 (3.1%) 183 (48.0%) 174 (45.7%) 2 (0.5%) 381 (22.0%)
G4 0 2 (5.9%) 2 (5.9%) 28 (82.4%) 2 (5.9%) 34 (2.0%)
Data shown are number (percent). Cohen’s Kappa for agreement between eGFRcreat and eGFRcreat-cys = 0.13.
creat, creatinine; cys, cystatin C; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pmed.1002400.t004
Table 5. Baseline eGFRcreat category and reclassification using eGFRcreat-cys in all study participants.
Baseline eGFRcreat category eGFRcreat-cys category Total
G1/G2 G3a G3b G4 G5
G1/G2 249 (46.7%) 274 (51.4%) 10 (1.9%) 0 0 533 (30.8%)
G3a 37 (4.7%) 436 (55.6%) 309 (39.4%) 2 (0.3%) 0 784 (45.2%)
G3b 3 (0.8%) 13 (3.4%) 270 (70.9%) 95 (24.9%) 0 381 (22.0%)
G4 0 0 2 (5.9%) 31 (91.2%) 1 (2.9%) 34 (2.0%)
Data shown are number (percent). Cohen’s Kappa for agreement between eGFRcreat and eGFRcreat-cys = 0.37.
creat, creatinine; creat-cys, creatinine and cystatin C; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pmed.1002400.t005
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with a total cost of £8 per person. This lower cost results from fewer people being reclassified
in either direction (Table 7).
Fig 3. Bland–Altman plots comparing eGFRcreat to eGFRcys and eGFRcreat-cys. (A) eGFRcreat versus eGFRcys; (B) eGFRcreat versus
eGFRcreat-cys. Dashed lines show mean difference between the 2 estimates of glomerular filtration rate. Dotted lines show 95% CI for mean
difference between the 2 estimates. creat, creatinine; creat-cys, creatinine and cystatin C; cys, cystatin C; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pmed.1002400.g003
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Discussion
Our results indicate that for the majority with CKD stage 3 (confirmed by 2 eGFRcreat
values) in primary care, use of eGFRcys or eGFRcreat-cys results in lower estimates of GFR than
eGFRcreat. The use of eGFRcys as recommended by NICE to confirm an eGFRcreat-based diag-
nosis of CKD G3aA1 resulted in reclassification of 7.7% as not having CKD, but a far greater
proportion (59.0%) were reclassified as having more advanced CKD (G3b–G5). Thus, in a
Table 6. Risk prediction models for CKD progression in 999 participants and all-cause mortality in 1,732 participants using different estimating
equations for eGFR.
Risk prediction Estimating equation Odds ratio or hazard ratio (95% CI) P value AUROC
Models for KDIGO CKD progression eGFRcreat 0.984 (0.971–0.998) 0.023 0.722
eGFRcys 0.982 (0.971–0.993) 0.001 0.726
eGFRcreat-cys 0.978 (0.965–0.991) 0.001 0.726
Models for all-cause mortality eGFRcreat 0.973 (0.960–0.986) <0.001
eGFRcys 0.975 (0.963–0.987) <0.001
eGFRcreat-cys 0.967 (0.954–0.981) <0.001
All progression models are adjusted for age, sex, urine albumin-to-creatinine ratio, haemoglobin, bicarbonate, and diabetes. All odds ratios given per ml/
min/1.73 m2. All survival models are adjusted for age, sex, urine albumin-to-creatinine ratio, haemoglobin, albumin, bicarbonate, diabetes, and previous
cardiovascular disease. All hazard ratios are given per ml/min/1.73 m2.
AUROC, area under the receiver operating characteristic curve; CKD, chronic kidney disease; creat, creatinine; cys, cystatin C; creat-cys, creatinine and
cystatin C; eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes.
https://doi.org/10.1371/journal.pmed.1002400.t006





















Decrease 7.50 15 −563 11 −413
Diabetes schedule unchanged G1/G2, DM NICE DM 28 Nil 6 0 0 0
Exclude eGFR and uACR test from
annual review
G1/G2, HT NICE HT
127
Decrease 6.19 29 −180 22 −136
Unchanged from annual GP
assessment of eGFR and uACR
G3a Nil 218 0 376 0




Increase 13.23 356 4,711 239 3,163
Nephrology, followed by biannual GP
assessment of eGFR and uACR3
G4, G5 NICE CKD
182
Increase 306.00 29 8,874 2 612
Total increase 12,843 3,226
Increase £/patient (monitoring) 20 5
Total increase £/patient 23 8
1References are NICE guidance documents. Numbers in the column are guideline numbers (see https://www.nice.org.uk/guidance).
2Unit cost for biannual assessment assumes this involves 1 additional visit to a practice nurse with phlebotomy for eGFR and uACR testing.
3Unit cost for nephrology followed by biannual GP visit assumes this involves 1 extra outpatient consultation plus 1 additional visit to a practice nurse with
phlebotomy for eGFR and uACR testing.
CKD, chronic kidney disease; creat-cys, creatinine and cystatin C; cys, cystatin C; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; GFR,
glomerular filtration rate; GP, general practitioner; HT, hypertension; NICE, National Institute for Health and Care Excellence; uACR, urine albumin-to-
creatinine ratio.
https://doi.org/10.1371/journal.pmed.1002400.t007
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primary care setting, the potential benefit of reducing over-diagnosis of CKD with eGFRcys
would be eliminated by the unintended consequence of greater reclassification to more
advanced CKD requiring more frequent monitoring and increased referrals to secondary care.
Additionally, the use of eGFRcys did not improve discrimination in risk prediction models in a
primary care population. Overall estimated costs would be increased by £23 per patient with
eGFRcys and £8 per patient with eGFRcreat-cys.
Our results differ in many respects from those of a large meta-analysis that evaluated the
clinical impact of using cystatin C versus creatinine to estimate GFR in 11 general population
cohorts and 5 CKD cohorts [23]. In the meta-analysis, though no difference was observed in
mean eGFR calculated by the different methods, use of eGFRcys resulted in a higher prevalence
of eGFR< 60 ml/min/1.73 m2 than either eGFRcreat or eGFRcreat-cys (13.7%, 9.7%, and 10.0%,
respectively). On the other hand, use of eGFRcys resulted in reclassification of 35%–47% of par-
ticipants with CKD G3a to GFR 60 ml/min/1.73 m2, whereas a lower proportion (21%–
27%) were reclassified to CKD G3b or worse. Moreover, reclassification to a less severe cate-
gory was associated with lower risks of all-cause mortality, cardiovascular mortality, and
ESKD [23]. One reason for the differences between these observations and ours is important
differences in the cohorts studied. The mean age of 60 and 55 years for the general population
and CKD cohorts, respectively, was substantially lower than the mean age of our cohort (73
years). This is an important distinction because our cohort is more representative of the major-
ity of people affected by CKD in developed countries with predominantly white populations.
A second important difference is that the studies included in the meta-analysis relied on only 1
abnormal eGFRcreat for the diagnosis of CKD, whereas we required confirmation with 2 abnor-
mal eGFRcreat values at least 90 days apart for study eligibility. In our study, those classified as
CKD G3a at baseline therefore had a minimum of 3 abnormal eGFRcreat values. It is likely that
simply retesting eGFRcreat would have reclassified a proportion of those included in the meta-
analysis as not having CKD, and this would reduce the impact of reclassification by eGFRcys.
In a population-based study in England, use of eGFRcys resulted in a higher prevalence of
CKD G3–G5 than eGFRcreat (7.7% versus 5.2%, respectively) [17]. In this study, similar to the
above meta-analysis, 37% of those with CKD G3aA1 defined by eGFRcreat were reclassified by
eGFRcys as not having CKD, but the proportion reclassified to an eGFR category indicating
more severe CKD was not reported. Like the meta-analysis, the participants in this study were
much younger than our cohort (median age 50 years), and only a single creatinine measure-
ment was used to define CKD. In addition, the cystatin C assay used was not standardised to
international reference material, and the CKD-EPI equation could not be used [17]. In con-
trast, an analysis of National Health and Nutrition Examination Survey data revealed higher
prevalence of reduced GFR by eGFRcys than eGFRcreat in both diabetic and non-diabetic par-
ticipants [24].
In our study, eGFRcys identified a higher proportion of participants as having progressive
CKD (18.2%) than eGFRcreat (10.5%) or eGFRcreat-cys (13.5%). Thus, in addition to the impact
of the lower baseline eGFR values seen with eGFRcys, higher apparent progression rates would
further promote the referral of patients from primary to secondary care. One could argue that
increased referral would be appropriate if patients were at increased risk, but the very low rate
of progression to ESKD observed in our study population after 5 years (0.2%) [21] implies that
use of eGFRcys in this primary care population would tend to increase referrals and frequency
of testing of people with low-risk disease who would be unlikely to benefit.
There is ongoing debate concerning the appropriateness of diagnosing CKD in older people
with category G3a eGFR and no proteinuria [25]. In this analysis, we applied current guide-
lines to diagnosis of CKD in our cohort. We have previously described the low rates of CKD
progression and relatively high rates of ‘remission’ in this population [21]. Additionally, recent
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results from the Berlin Initiative Study (BIS) have shown that eGFR in older adults strongly
depends upon the estimating equation used [26]. The BIS equations (creatinine only and com-
bined creatinine and cystatin C) were developed in a cohort of people over the age of 70 years.
These equations tend to produce lower eGFR values than the corresponding CKD-EPI equa-
tions and are more accurate in predicting measured GFR [27]. Comparable results have been
shown using the full age spectrum (FAS) equation [28]. Our study focussed on the CKD-EPI
equations as these have been incorporated into KDIGO and NICE guidance and are in wide-
spread use clinically.
Several studies have reported that, like all endogenous markers of GFR, serum cystatin C
concentration is independently associated with several non-GFR determinants including age,
sex, diabetes, markers of obesity, inflammation, and smoking [10–13]. Though we did not
have measured GFR data, multivariable analysis corrected for eGFRcreat confirmed indepen-
dent associations of eGFRcys with age, serum albumin, serum uric acid, haemoglobin, BMI,
uACR, hsCRP, and current smoking (S1 Table) [29]. These observations are important
because several of these non-GFR determinants are also risk factors for cardiovascular disease,
and this may in part explain the better performance of eGFRcys as a risk factor for adverse out-
comes in CKD cohorts and populations without CKD. Indeed, some have suggested that the
ability of cystatin C concentration to predict mortality may have little to do with its association
with GFR but instead is largely attributable to the non-GFR determinants of cystatin C [30,31].
Alternatively, other investigators have proposed that in states of inflammation, filtration of
cystatin C at the glomerulus is impaired, producing underestimates of GFR [32]. In addition,
understanding the non-GFR determinants of cystatin C is important for identifying patient
groups in whom eGFRcys will be unreliable. Our data, though limited by lack of measured
GFR, confirm previous reports suggesting that eGFRcys is likely to be less accurate for estimat-
ing GFR in elderly and obese patients as well as those with albuminuria or evidence of inflam-
mation and in current smokers. However, there may be situations where measurement of
eGFRcys may be preferred to eGFRcreat, for example in the assessment of renal function in
younger people with extremes of body habitus and muscle mass.
Reduced GFR is widely recognised as an independent risk factor for multiple adverse out-
comes including acute kidney injury, ESKD, cardiovascular mortality, and all-cause mortality
[33–35]. Several papers have reported improved discrimination if eGFRcys is used in risk predic-
tion analyses instead of eGFRcreat, though it is unclear whether this is due to improved GFR esti-
mation or associations with the non-GFR determinants of cystatin C. In our cohort, eGFRcys did
not improve discrimination in risk prediction analyses for CKD progression or all-cause mortal-
ity, suggesting that widespread use in primary care will not improve risk prediction [15,16].
Our assessment of the cost associated with implementing NICE guidance to use eGFRcys to
confirm a diagnosis in those classified as CKD G3aA1 by eGFRcreat resulted in an overall
increase in cost of £23 per patient because the cost savings resulting from reduced numbers
diagnosed with CKD were far outweighed by the increased costs associated with a requirement
for increased monitoring and referral in the large proportion reclassified to a more advanced
stage of CKD. The total number of patients meeting the inclusion criteria of this study in the
adult population of England can be estimated approximately from the Health Survey for
England as 1.36 million (prevalence in adults of G3aA1 of 3.2%) [9]. If the increase of £23 per
patient due to implementation of the NICE guidance was applied to each of these patients, the
total additional cost to the NHS would be approximately £31 million per year. A lower total
national cost of about £11 million would apply if instead the combined eGFRcreat-cys equation
was used. This cost could potentially be justified if the use of eGFRcys were associated with
higher-risk patients being successfully treated with more intensive treatment or referral, but
we were unable to demonstrate improved risk prediction in this predominantly low-risk study
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population. In interpreting these national cost extrapolations, it should be remembered that,
like most epidemiological studies, the Health Survey for England measured only a single eGFR
value and may therefore have overestimated the true prevalence of CKD G3aA1.
Study strengths and limitations
Important strengths of this study are individual recruitment and clinical assessment at base-
line, prospective protocol-driven follow-up, and a requirement for 2 eGFR readings of<60
ml/min/1.73 m2 prior to inclusion in the study cohort [36,37]. This last strength is of particular
significance because the majority of published studies have adopted the epidemiological study
approach of requiring only 1 abnormal eGFR for CKD diagnosis. Moreover, our study popula-
tion was predominantly elderly, and most participants had only mildly reduced GFR. This is
typical of the majority affected by CKD in developed countries [8] and is representative of pop-
ulations in which NICE and KDIGO anticipated that use of eGFRcys would reduce over-diag-
nosis of CKD. We were also able to evaluate the short-term cost implication of using the
different equations.
We must, however, concede several important limitations of the study. We were limited by
the lack of a measured GFR at baseline in order to compare estimating equations to a ‘gold
standard’. However, the aim of this study was to assess primarily the clinical impact of intro-
ducing eGFRcys in primary care, where few people have a measured GFR, rather than the accu-
racy of the estimating equations. Few people with CKD have a measured GFR, and our study
therefore reflects the situation in clinical practice. The lack of a measured GFR also impacts
upon our assessment of non-GFR determinants of eGFRcys due to potential confounding by
non-GFR determinants of eGFRcreat (used as a correction in the analysis instead of measured
GFR). Nevertheless, our results are consistent with previous published studies and strengthen
the evidence by showing that non-GFR determinants of cystatin C are an important consider-
ation in the primary care setting. The risk prediction models described in this paper were used
to show that the use of eGFRcys did not improve discrimination compared to eGFRcreat in this
cohort. It was not our intention to develop risk prediction models for general application, and
we concede that external validation would be required before this could be recommended.
Our study population was predominantly white and elderly (mean age 73 years), and most had
only mild reductions in GFR (mean eGFRcreat 53.6 ml/min/1.73 m
2). As discussed above, this
is in some respects a strength, but we concede that our results may not be applicable to youn-
ger or more ethnically diverse populations or to those in secondary care with more advanced
CKD. The number of events of death and CKD progression was also relatively low, and we
may therefore have lacked statistical power to detect minor improvement in risk prediction
with eGFRcys. Our cost impact analysis was limited to the year of introduction of cystatin C
testing. Lifetime (or long term) costing would require more complex modelling that is beyond
the scope of this paper.
Conclusions
We have found that in an elderly population in primary care, application of NICE and KDIGO
recommendations to use eGFRcys to confirm a diagnosis of CKD in those classified as CKD
G3aA1 by eGFRcreat results in a greater proportion of individuals being reclassified to an eGFR
category indicating more severe CKD than reclassified to an eGFR category indicating no
CKD. Additionally, eGFRcys cannot be recommended to improve risk prediction in this popu-
lation because it did not improve discrimination in risk prediction models for adverse out-
comes compared to eGFRcreat. Our data therefore do not support implementation of these
recommendations in primary care. Nevertheless, it is likely that eGFRcys will be helpful in
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obtaining a more accurate estimate of GFR in people at extremes of muscle mass, in whom
eGFRcreat is known to be inaccurate, but account should also be taken of the non-GFR deter-
minants of cystatin C. Further studies are warranted to define the most appropriate clinical
application of eGFRcys and eGFRcreat-cys.
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